Who are Remi 0.2's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Effexor, Initial conversion and titration.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/remi-0-2.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Remi 0.2 — Competitive Intelligence Brief

Remi 0.2 (Remi 0.2) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: SNRI (Serotonin-Norepinephrine Reuptake Inhibitor). Area: Psychiatry.

marketed SNRI (Serotonin-Norepinephrine Reuptake Inhibitor) Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

Remi 0.2 (Remi 0.2) — Dokuz Eylul University. Remi 0.2 is a medication that works by inhibiting the reuptake of serotonin and norepinephrine.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Remi 0.2 TARGET	Remi 0.2	Dokuz Eylul University	marketed	SNRI (Serotonin-Norepinephrine Reuptake Inhibitor)
Effexor	venlafaxine	Generic (originally Wyeth/Pfizer)	marketed	SNRI (Serotonin-norepinephrine reuptake inhibitor)	5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2C	1993-12-28
Initial conversion and titration	Initial conversion and titration	St. Joseph's Hospital and Medical Center, Phoenix	marketed	SNRI (Serotonin-Norepinephrine Reuptake Inhibitor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (SNRI (Serotonin-Norepinephrine Reuptake Inhibitor) class)

Dokuz Eylul University · 1 drug in this class
St. Joseph's Hospital and Medical Center, Phoenix · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Remi 0.2 — Competitive Intelligence Brief. https://druglandscape.com/ci/remi-0-2. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab